Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

24.37USD
3:59pm EST
Change (% chg)

$1.84 (+8.17%)
Prev Close
$22.53
Open
$22.54
Day's High
$25.89
Day's Low
$22.44
Volume
685,563
Avg. Vol
129,474
52-wk High
$26.01
52-wk Low
$9.40

ESPR.OQ

Chart for ESPR.OQ

About

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $508.14
Shares Outstanding(Mil.): 22.55
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 46.85 29.68
EPS (TTM): -2.62 -- --
ROI: -21.31 -3.61 13.06
ROE: -21.48 5.27 14.19

BRIEF-Esperion posts Q4 loss per share $1.29

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

Feb 22 2017

BRIEF-Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of Bempedoic Acid

* Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of bempedoic acid in patients with hypercholesterolemia

Jan 25 2017

BRIEF-Esperion Therapeutics reports qtrly loss per share $0.77

* Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million

Nov 03 2016

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

Oct 13 2016

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

Sep 27 2016

More From Around the Web

Earnings vs. Estimates